このエントリーをはてなブックマークに追加
ID 62030
フルテキストURL
fulltext.pdf 2.14 MB
著者
Nasu, Atsuko Division of Pathophysiology, Okayama University Graduate School of Health Sciences
Gion, Yuka Division of Pathophysiology, Okayama University Graduate School of Health Sciences Kaken ID researchmap
Nishimura, Yoshito Department of General Medicine, Okayama University Hospital ORCID publons researchmap
Nishikori, Asami Division of Pathophysiology, Okayama University Graduate School of Health Sciences
Sakamoto, Misa Division of Pathophysiology, Okayama University Graduate School of Health Sciences
Egusa, Yuria Division of Pathophysiology, Okayama University Graduate School of Health Sciences
Fujita, Azusa Division of Pathophysiology, Okayama University Graduate School of Health Sciences
Yoshino, Tadashi Department of Pathology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine Kaken ID publons researchmap
Sato, Yasuharu Division of Pathophysiology, Okayama University Graduate School of Health Sciences ORCID Kaken ID researchmap
抄録
Differentiation between adult T-cell leukemia/lymphoma (ATLL) and peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is often challenging based on pathological findings alone. Although serum anti-HTLV-1 antibody positivity is required for ATLL diagnosis, this information is often not available at the time of pathological diagnosis. Therefore, we examined whether the expression of SOX4 and p16 would be helpful for differentiating the two disease entities. We immunohistochemically examined SOX4 and p16 expression (which have been implicated in ATLL carcinogenesis) in 11 ATLL patients and 20 PTCL-NOS patients and classified them into four stages according to the percentage of positive cells. Among the ATLL cases, 8/11 (73%) were SOX4-positive, while only 2/20 (10%) PTCL-NOS cases expressed SOX4. The mean total score was 4.2 (standard deviation (SD): 0.61) in the ATLL group and 0.50 (SD: 0.46) in the PTCL-NOS group (p < 0.001). Positive expression of p16 was noted in 4/11 (36%) patients with ATLL and 3/20 (15%) patients with PTCL-NOS, with mean total scores of 1.9 (SD: 0.64) and 0.70 (SD: 0.48) in the ATLL and PTCL-NOS groups, respectively (p = 0.141). These results suggest that SOX4 may be strongly expressed in ATLL compared to PTCL-NOS cases. Therefore, it may be helpful to perform immunohistochemical staining of SOX4 when pathologists face challenges discriminating between ATLL and PTCL-NOS.
キーワード
SOX4
p16
adult T-cell leukemia/lymphoma
peripheral T-cell lymphoma
not otherwise specified
発行日
2021-04-24
出版物タイトル
Diagnostics
11巻
5号
出版者
MDPI
開始ページ
766
ISSN
2075-4418
資料タイプ
学術雑誌論文
言語
English
OAI-PMH Set
岡山大学
著作権者
© 2021 by the authors.
論文のバージョン
publisher
PubMed ID
NAID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.3390/diagnostics11050766
ライセンス
https://creativecommons.org/licenses/by/4.0/